HL3501, a Novel Selective A3 Adenosine Receptor Antagonist, Lowers Intraocular Pressure (IOP) in Animal Glaucoma Models

PURPOSE: The A3 adenosine receptor (A3AR) is a known therapeutic target for glaucoma treatment. In this study, we developed HL3501 and examined its selectivity profile and in vitro and in vivo effects. METHODS: For the rabbit model, intraocular pressure (IOP) was increased by laser photocoagulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yunhee, Yang, Jaewook, Kim, Jee Young, Lee, Jang Mi, Son, Woo Chan, Moon, Byoung-Gon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883152/
https://www.ncbi.nlm.nih.gov/pubmed/35191964
http://dx.doi.org/10.1167/tvst.11.2.30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883152/
https://www.ncbi.nlm.nih.gov/pubmed/35191964
http://dx.doi.org/10.1167/tvst.11.2.30

Ejemplares similares